CADX’s claim to fame is Ofirmev, an IV formulation of acetaminophen for hospital use. The nominal deal value is $1.3B. MNK was the 2013 pharma spin-off from COV, which was itself spun off from Tyco in 2007.
CC at 8:30am ET.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”